Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 15, 2009

Chilean Firm CeTeCancer to Evaluate Radient’s Lung Cancer IVD for Clinical Applications

  • CeTeCancer, a Chilean-based research laboratory, has agreed to validate Radient Pharmaceuticals’ Onko-Sure™ in vitro diagnostic (IVD) as a tool for the early detection and prevention of lung cancer. CeTeCancer will provide clinical samples and perform all clinical testing.

    The project is supported by Innova Corfo and will run for 18 months. Final results are anticipated to be published in early 2011.

    Onko-Sure is a noninvasive blood test that is designed for the detection and/or monitoring of 14 different types of cancer including lung, breast, stomach, liver, colon, rectal, ovarian, esophageal, cervical, trophoblastic, thyroid, malignant lymphoma, and pancreatic. It is sold as a blood test for cancer in Europe, India, Taiwan, Korea, and Vietnam as well as for research use in Chile.

    It also has FDA clearance for the monitoring of colorectal cancer. Additionally, the test is approved in Canada for lung cancer detection and lung cancer treatment monitoring.

     



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »